Article
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
The oncologist - 1 Sept 2015
Goyal Lipika, Govindan Aparna, Sheth Rahul A, Nardi Valentina, Blaszkowsky Lawrence S, Faris Jason E, Clark Jeffrey W, Ryan David P, Kwak Eunice L, Allen Jill N, Murphy Janet E, Saha Supriya K, Hong Theodore S, Wo Jennifer Y, Ferrone Cristina R, Tanabe Kenneth K, Chong Dawn Q, Deshpande Vikram, Borger Darrell R, Iafrate A John, Bardeesy Nabeel, Zheng Hui, Zhu Andrew X
Abstract excerpt
BACKGROUND: Conflicting data exist regarding the prognostic impact of the isocitrate dehydrogenase (IDH) mutation in intrahepatic cholangiocarcinoma (ICC), and limited data exist in patients with advanced-stage disease. Similarly, the clinical phenotype of patients with advanced IDH mutant (IDHm) ICC has not been characterized. In this study, we report the correlation of IDH mutation status with prognosis and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.